Allogene Therapeutics Inc (NASDAQ:ALLO)’s share price was up 5% on Friday . The stock traded as high as $29.90 and last traded at $29.51. Approximately 504,716 shares traded hands during trading, an increase of 18% from the average daily volume of 427,902 shares. The stock had previously closed at $28.10.

Several equities analysts have recently weighed in on ALLO shares. Jefferies Financial Group started coverage on shares of Allogene Therapeutics in a research report on Monday, November 5th. They set a “buy” rating and a $31.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on shares of Allogene Therapeutics in a research note on Monday, November 5th. They set a “neutral” rating and a $29.00 price objective for the company. Cowen initiated coverage on shares of Allogene Therapeutics in a research note on Monday, November 5th. They set an “outperform” rating for the company. Goldman Sachs Group initiated coverage on shares of Allogene Therapeutics in a research note on Monday, November 5th. They set a “buy” rating and a $41.00 price objective for the company. Finally, Zacks Investment Research raised shares of Allogene Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research note on Monday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Allogene Therapeutics has an average rating of “Buy” and an average target price of $32.75.

In related news, major shareholder Group Holdings (Sbs) Advis Tpg purchased 675,000 shares of Allogene Therapeutics stock in a transaction dated Monday, October 15th. The stock was acquired at an average cost of $18.00 per share, with a total value of $12,150,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider David D. Chang purchased 40,000 shares of Allogene Therapeutics stock in a transaction dated Monday, October 15th. The stock was bought at an average cost of $18.00 per share, with a total value of $720,000.00. The disclosure for this purchase can be found here. Insiders bought 750,000 shares of company stock valued at $13,500,000 over the last three months.

WARNING: “Allogene Therapeutics (ALLO) Trading Up 5%” was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/allogene-therapeutics-allo-trading-up-5/2740717.html.

About Allogene Therapeutics (NASDAQ:ALLO)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent.

Recommended Story: Municipal Bonds

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.